Clinical Trial Update: Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell Therapy

View source ↗

Summary

The trial investigating immunological, neurocognitive, activity, and driving fitness outcomes in CAR-T cell therapy for hematologic neoplasms has been withdrawn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Neoplasms

Drugs mentioned

• CAR-T cell therapy

Snippet

Sponsor: University of Nebraska | Conditions: Hematologic Neoplasms | Status: WITHDRAWN